{
}
UBS has maintained a "Neutral" rating for Givaudan with a target price of 4,520 francs, following a recent conference. Analyst Charles Eden noted that there are no indications of a sales slowdown anticipated for the final quarter, alleviating previous concerns.
UBS AG has maintained a "Buy" rating for Symrise shares, setting a price target of 138 euros, following a recent analysis. The focus is on the upcoming capital market day on November 19-20, where updates on the 2024 margin target and growth prospects will be discussed. Currently, Symrise shares have risen by 6.0% since the start of 2024, with a potential upside of 32.12% based on the price target.
UBS AG maintains a "Buy" rating for Symrise shares, setting a target price of 139 euros, despite a 2.8% drop to EUR 112.35. Analyst Charles Eden noted that organic sales growth expectations were raised, but the third quarter's performance was partly negative compared to strong competitor results. The share has a potential upside of 23.72% relative to the target price, with a 14.0% gain over 2024, and Q4 earnings and sales figures are anticipated on March 5, 2025.
UBS AG has maintained a "Buy" rating for Symrise shares, setting a target price of 139 euros despite a recent decline in share price to 112.70 euros. Analyst Charles Eden noted that organic sales growth expectations were raised, although the third quarter showed partly negative results compared to strong figures from competitor Givaudan. The share has seen a 14% increase since the start of 2024, with a potential upside of 23.72% relative to the target price.
UBS has maintained its "Buy" rating for Symrise, setting a target price of 139 euros. Analyst Charles Eden noted an increase in the target for organic sales growth, although the third quarter's organic growth was viewed as partly negative due to heightened investor expectations following strong results from competitor Givaudan.
UBS has maintained a "Neutral" rating for Givaudan, setting a price target of 4,520 francs following an investor event focused on the fragrance business. Analyst Charles Eden noted ongoing discussions regarding the anticipated slowdown in growth within this segment and its potential impact on profitability.
Charles Eden
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS maintains neutral rating for Givaudan with target price of 4520 francs
11:37 14.11.2024
ubs maintains buy rating for symrise with price target of 138 euros
11:28 14.11.2024
ubs maintains buy rating for symrise with target price of 139 euros
10:43 24.10.2024
ubs maintains buy rating for symrise with target price of 139 euros
10:43 24.10.2024
UBS maintains buy rating for Symrise with target price of 139 euros
09:53 24.10.2024
UBS maintains neutral rating for Givaudan amid fragrance business concerns
07:07 23.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Global Trade Developments
Stock Market Updates
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Cryptocurrency Trends
Private Equity Deals
Government Economic Policies
Central Bank Actions
Central Banks and Digital Currencies
Fintech Startups
CEO Changes
Workplace Trends
Blockchain Infrastructure Development
Crypto Policies and Governance
Banking Regulations
Finance Mergers & Acquisitions
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Tesla, Inc.
MARA Holdings, Inc.
Cleanspark Inc
Citigroup Inc.
Vodafone Idea Limited
JM Financial Limited
Fuse Science, Inc.
Arla Foods A.M.B.A.
Currencies:
United States Dollar
Euro
Chinese Yuan
Indian Rupee
New Taiwan Dollar
Egyptian Pound
Hong Kong Dollar
Malaysian Ringgit
Indonesian Rupiah
Filipino Peso
West African CFA Franc
Japanese Yen
People: